<DOC>
	<DOCNO>NCT00367822</DOCNO>
	<brief_summary>The objective trial compare individually optimize dose lisuride TTS patch placebo individually optimize dose oral ropinirole ( active- placebo-controlled design ) idiopathic uremic RLS patient regard efficacy , safety , quality life .</brief_summary>
	<brief_title>Transdermal Lisuride : Trial Treatment Patients With Restless Legs Syndrome ( RLS )</brief_title>
	<detailed_description>Approximately 300 patient randomize receive either lisuride , ropinirole placebo 2:1:1 fashion . After completion 12 week double-blind treatment , eligible patient option continue treatment lisuride patch 36 week open-label extension study . Primary outcome : Changes total score International Restless Legs Severity Scale ( IRLS ) baseline end double-blind treatment ( 12 week ) use primary efficacy outcome measure . Secondary objective evaluate quality life , safety tolerability . After double-blind period , long-term efficacy lisuride assess 36 week open-label extension study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<mesh_term>Lisuride</mesh_term>
	<criteria>Idiopathic uremic RLS RLS Diagnostic Index ( RLSDI ) &gt; 10 Total score IRLS Rating Scale â‰¥ 15 baseline No previous treatment RLS insufficient current therapy Secondary RLS , e.g . due iron deficiency ( exception : uremia ) History presence sleep disorder RLS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Restless Legs Syndrome</keyword>
	<keyword>dopamine agonist</keyword>
	<keyword>lisuride</keyword>
	<keyword>ropinirole</keyword>
</DOC>